Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
Would you considering substituting infusional 5FU for capecitabine in the FLOT regimen for localized gastric adenocarcinoma?
Answer from: Medical Oncologist at Academic Institution
No. I'm not aware of any high-quality data for such a regimen.
Sign in or Register to read more
3092
Related Questions
What factors do you consider when deciding between dual vs single-agent immunotherapy for patients with MSI-H or dMMR metastatic CRC?
Would you rechallenge with cabozantinib in a patient with HCC after the development of a 6 mm gastrohepatic fistula without perforation or communication with the peritoneal cavity?
Of the two ipilimumab dosing schedules utilized with nivolumab on CheckMate 8HW, do you have a preference in your own practice?
What are your top takeaways in GI Cancers from ESMO 2024?
What factors would make you choose IPI3/NIVO1 frontline for advanced unresectable and metastatic HCC based on CheckMate 9DW?
What are your first line treatment choices for metastatic combined HCC/Cholangiocarcinoma?
Would you offer adjuvant therapy for resected GB cancer > 6 months of surgery time if there are high risk features (pT3N0, positive margins, + PNI) and therapy was delayed due to hepatic abscess post operative?
How do you best incorporate use of filgrastim/pegfilgrastim in capecitabine based regimens?
What are the treatment options for patients with duodenal cancer who have progressed on FOLFIRINOX?
What second-line therapy would you offer a patient with metastatic colon cancer with HER2 IHC 3+ amplification and KRAS G12D mutation whose disease progressed on FOLFOX?